Efficacy of percutaneous vocal fold injections for benign laryngeal lesions: Prospective multicenter study

Abstract

Among 115 patients in the study, 40 cases (34.8%) showed complete remission and 57 cases (49.6%) showed partial remission. As a result, overall improvement rates were 84.4%. Almost all objective and subjective parameters showed statistical improvement at the first and third month after PSI (p < 0.05). Jitter and all subjective parameters maintained statistical improvement until the sixth month. No severe complications, such as fold atrophy, were observed.

Glucocorticoids in laryngology: A review

“…Similar results were reported in a prospective multicenter trial . One hundred fifteen patients with a variety of benign vocal fold lesions, including nodules, polyps, scar, and Reinke's edema, who had refused voice therapy or general anesthesia, were treated with percutaneous injection of triamcinolone via transthyrohyoid, transcricothyroid, or transcartilage approaches.…”

Comprehensive Outcome Researches of Intralesional Steroid Injection on Benign Vocal Fold Lesions

“…14 For example, although triamcinolone's depot nature can result in longer duration of effectiveness within the injected site, 13 transient impairment of vocal fold vibration might occur after thick plaque formation of the injected triamcinolone, with incidence rates varying from 2.5% to nearly 100%. 36,46,47 Such inconsistent results might be explained by different time frames for postoperative visits. Because the triamcinolone is mostly absorbed gradually, it was likely that subjects returning to the clinic earlier were more likely to reveal such adverse effects than subjects who return to the clinic after 1-2 months.…”

“…13,46 Compared with the transcutaneous approach in which the needle migrates in subepithelial direction without interrupting the epithelium of the vocal folds, 36,46 the transoral and transnasal injection approaches performed in this series require direct puncture of the injection needle through the upper epithelial cover of the vocal fold, which may result in higher rates of postoperative hematoma. Similarly, time between intervention to clinical follow-up might also have altered the incidence rates of vocal hematoma because these adverse effects tended to regress spontaneously within 1-2 months.…”

Smad3: An emerging target for vocal fold fibrosis

“…In contrast, the treatment of vocal fold scar remains suboptimal. The one exception may be localized steroid injections, which have been reported to show modest, unreliable success in limited case series . We posit that an ideal therapy for vocal fold fibrosis must have targeted and predictable control of both the inflammatory and subsequent fibroplastic phenotype.…”